6-K

0001193125-26-180848.txt : 20260427 0001193125-26-180848.hdr.sgml : 20260427 20260427125810 ACCESSION NUMBER: 0001193125-26-180848 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133529324 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31368 FILM NUMBER: 26898545 BUSINESS ADDRESS: STREET 1: 46 AVENUE DE LA GRANDE ARMEE CITY: PARIS STATE: I0 ZIP: 75017 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 46 AVENUE DE LA GRANDE ARMEE CITY: PARIS STATE: I0 ZIP: 75017 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 6-K 1 d137048d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

In April 2026, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5 which are incorporated herein by reference.

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press Release dated April 18, 2026: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Exhibit 99.2		Press Release dated April 22, 2026: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Exhibit 99.3		Press Release dated April 22, 2026: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Exhibit 99.4		Press Release dated April 22, 2026: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Exhibit 99.5		Press Release dated April 24, 2026: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated: April 27, 2026		SANOFI


By		/s/ Alexandra Roger
		Name: Alexandra Roger
		Title: Head of Legal Corporate & Finance

EX-99.1 2 d137048dex991.htm EX-99.1 EX-99.1

Exhibit 99.1


Press Release

ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

•

First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world setting

•

Results were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany.

Paris, April 18, 2026. Sanofi’s protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE (mRNA-1283), Moderna’s latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study. The randomized, double-blind study, which enrolled 1,000 adults in the US, was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany.

These results address a persistent challenge: despite the end of the pandemic, COVID-19 continues to cause significant hospitalizations and deaths globally, while placing considerable strain on health systems during seasonal peaks. Yet vaccination uptake remains low, with concerns about vaccine side effects ranking among the top reasons cited by adults for not getting vaccinated against COVID-19.

In the COMPARE study, when side effects did occur with Nuvaxovid, they were less severe and shorter in duration compared to mNEXSPIKE. Severe systemic symptoms (body-wide reactions such as fatigue, headache, or fever) that prevent people from carrying out their normal daily activities were more than 50% less frequent with Nuvaxovid, affecting fewer than one in ten Nuvaxovid recipients compared to one in five mNEXSPIKE recipients, an analysis of the data showed. Severe local symptoms (reactions at the injection site such as pain, redness, or swelling) with Nuvaxovid were rare, and more than 75% less frequent compared to mNEXSPIKE. This was reflected in the study participants’ own experience: those who received Nuvaxovid were nearly twice as likely as mNEXSPIKE recipients to say they would definitely choose the same vaccine type again the following year.

The study met its primary endpoint – the probability of experiencing at least one systemic reaction within seven days of vaccination - with statistical significance, with 91.6% of mNEXSPIKE recipients affected compared to 83.6% of Nuvaxovid recipients (risk difference: 8.0%; 95% CI: 4.0%–12%; p<0.001).

The study also showed that 61.3% of mNEXSPIKE recipients experienced moderate-to-severe (Grade 2 or 3) systemic symptoms versus 43.1% of Nuvaxovid recipients (risk difference: 18%; 95% CI: 12%–24%; p<0.001), and 58.7% of mNEXSPIKE recipients experienced moderate-to-severe local symptoms versus 38.7% of Nuvaxovid recipients (risk difference: 20%; 95% CI: 14%–26%; p<0.001).

“This study was designed to answer a question that matters deeply to clinicians and patients alike: how do different COVID-19 vaccines compare in terms of reactogenicity and patient experience? The answer is clear,” said Dr. Marcel E. Curlin, Principal Investigator of the COMPARE study and Professor of Medicine at Oregon Health & Science University. “Across every measure we evaluated, we observed that the recombinant protein-based vaccine consistently exhibited lower reactogenicity and less disruption to patient activities than the comparator mRNA vaccine. Individuals cite side effects as a reason they avoid COVID-19 vaccination. These differences could have a significant impact on improving vaccination uptake.”


		1/3

“The patient experience with vaccination is essential, because it determines not only whether people get vaccinated, but also whether they come back year after year for routine protection,” said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi. “These results show that Nuvaxovid can play a meaningful role in making routine COVID-19 vaccination a reality for more people, which is how we can help address the continued burden of this disease on patients and health systems.”

Beyond clinical measures, the COMPARE study also captured patient-reported outcomes reinforcing the real-world relevance of Nuvaxovid’s tolerability profile. Nuvaxovid recipients reported less disruption to daily activities, including work, school, recreational activities, and caretaking responsibilities, over the seven days following vaccination. Notably, more than half of all participants reported scheduling their vaccination on a specific day of the week in anticipation of potential side effects, highlighting the extent to which tolerability concerns shape vaccination behavior. Together, these findings suggest that a better tolerability experience may favor greater vaccine confidence and willingness to return for routine immunization.

About COVID-19

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill resulting in hospitalization and death.

The disease not only causes immediate health impacts but also increases the long-term risk of cardiovascular complications, including heart attacks and strokes, and older adults hospitalized for COVID-19 face substantially higher mortality risk than those hospitalized for influenza. Older adults and those with chronic conditions - including cardiovascular disease, chronic lung disease, diabetes, and obesity - face the highest risk of severe illness. In the US, an estimated 74% of adults have at least one such risk factor, underscoring the scale of the vulnerable population that stands to benefit from effective and well-tolerated COVID-19 vaccination.

About Nuvaxovid

Nuvaxovid (NVX-CoV2705) is a protein-based, adjuvanted vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2. It is developed using the recombinant technology, an established platform with a long track record across multiple vaccine types. Nuvaxovid has been shown to have a tolerable side-effect profile suitable for routine vaccination and has also demonstrated high efficacy against COVID-19 as a primary vaccination in two pivotal phase 3 studies.

As the pandemic has now evolved into an endemic phase, having multiple vaccine options becomes increasingly important for sustainable public health strategies. Nuvaxovid offers healthcare systems a protein-based vaccine option with an established safety and tolerability profile to add to their routine vaccination programs. This diversity is particularly valuable for addressing vaccine hesitancy.

Nuvaxovid was originally licensed by Novavax. Sanofi is now market authorization holder for Nuvaxovid in the US, the EU and the United Kingdom. Building on its commercial launch in the US, Taiwan, and Morocco in 2025, Sanofi is expanding Nuvaxovid’s availability to additional markets - including the United Kingdom, Germany, and Canada - from 2026 onwards.

About Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY


		2/3

Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com

Investor Relations

Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statement

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.


		3/3

EX-99.2 3 d137048dex992.htm EX-99.2 EX-99.2

Exhibit 99.2


Press Release

Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its review of the biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved US indications of Sarclisa intravenous (IV) formulation. The revised target action date for the FDA decision is July 23, 2026.

Sanofi is committed to working closely with the FDA to bring this new advancement to patients and providers as quickly as possible. If approved, Sarclisa would be the first anticancer treatment to be administered through an on-body injector (OBI).

On March 26, 2026, the European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Sarclisa SC administered via both an OBI and manual injection for the treatment of MM patients across all currently approved indications and combinations for Sarclisa IV formulation in the EU. A final decision is expected in the coming months.

About Sarclisa

Sarclisa (isatuximab-irfc) has been approved in almost 60 countries across four indications for certain patients with newly diagnosed MM and relapsed or refractory MM. Sarclisa-based regimens have been prescribed to treat more than 60,000 patients worldwide.

At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need.

For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov.

About Sanofi

Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Investor Relations

Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com


		1/2

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.

Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these, and similar expressions are intended to identify forward-looking statements.

Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group.


		2/2

EX-99.3 4 d137048dex993.htm EX-99.3 EX-99.3

Exhibit 99.3


Press Release

Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

•

Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3

•

Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D

Paris, April 22, 2026. The US Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under a priority review process and is supported by one-year data from the PETITE-T1D phase 4 study (clinical study identifier: NCT05757713), evaluating safety and pharmacokinetics in young children.

“This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” said Kimber Simmons, MD, MS, Associate Professor of Pediatrics at the Barbara Davis Center, Aurora, Colorado, US. “This is especially important because these children are often at the highest risk of progressing quickly and without warning. Delaying the onset of stage 3 type 1 diabetes during the years when management is often most difficult because of a child’s small size and dependence on caregivers could have a truly meaningful impact for families.”

“The autoimmune attack driving this disease often begins early in life, and the burden that autoimmune T1D poses in this very young population and their families is significant,” said Christopher Corsico, Global Head of Development at Sanofi. “This approval underscores the importance of targeting the immune system early in autoimmune type 1 diabetes, aiming to impact its natural progression by delaying the loss of insulin production in the pancreas.”

Tzield is also being reviewed by the FDA for a potential indication to delay the progression of stage 3 T1D in patients eight years of age and older recently diagnosed with stage 3 T1D.

Tzield is approved in the EU (under the name Teizeild), in the UK, China, Canada, Israel, Saudi Arabia, the UAE, Kuwait, and Brazil to delay the onset of stage 3 T1D in adults and pediatric patients eight years and older diagnosed with stage 2 T1D. Other regulatory reviews are ongoing. Tzield was previously granted FDA breakthrough therapy designation and orphan drug designation, for medicines that treat rare diseases affecting fewer than 200,000 people in the US.

About PETITE-T1D

PETITE-T1D (clinical study identifier: NCT05757713) is a phase 4 single-arm, non-randomized, open-label, multi-center study designed to assess the safety and pharmacokinetics of Tzield in children under eight years diagnosed with stage 2 T1D. Stage 2 T1D is defined by the presence of two or more T1D-related autoantibodies and abnormal blood sugar levels (dysglycemia).

The study has enrolled 23 participants. The regimen consists of an intravenous infusion of Tzield once daily for 14 consecutive days. The study duration for each individual may last up to 26 months including screening for eligibility, treatment administration and follow-up.

About autoimmune T1D

T1D is a progressive autoimmune disease where the body’s ability to regulate blood sugar levels is impacted due to the gradual destruction of insulin-producing beta cells by one’s own immune system. There are four stages to the progression of T1D:


		1/3

•

In stage 1, the autoimmune attack to the beta cells has started, and this can be detected by the presence of two or more T1D-related autoantibodies in the blood. During stage 1, blood sugar levels are in a normal range (normoglycemia). At this stage, T1D is presymptomatic.

•

In stage 2 (also presymptomatic), in addition to the presence of two or more T1D-related autoantibodies, blood sugar levels become abnormal (dysglycemia) due to the progressive loss of beta cells / beta-cell function.

•

Stage 3 (also known as clinical stage) comes once a significant portion of the beta cells have been destroyed. At this point, rising blood sugar levels reach the point of clinical hyperglycemia (which defines diabetes), and many people will start to experience the classic symptoms that come with the onset of stage 3 T1D: increased thirst, frequent urination, unexplained weight loss, blurred vision, and generalized fatigue. Management of stage 3 T1D requires daily and burdensome insulin replacement therapy.

•

Stage 4 is defined as long-standing autoimmune T1D, often accompanied by evidence of chronic diabetic complications, where little to no beta-cell function remains (it has been estimated that beta-cell mass is reduced by up to 95%). At this point, the T1D-related autoantibodies might not be present anymore in the blood, as most beta cells have been rendered useless by the autoimmune attack.

About Tzield

Tzield (teplizumab-mzwv) is a CD3-directed monoclonal antibody. Tzield is the first disease modifying medicine in autoimmune T1D. It was first approved in the US in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. Tzield is also approved in the EU (under the name Teizeild), the UK, China, Canada, Israel, Saudi Arabia, the UAE, Kuwait, and Brazil to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D.

About Sanofi

Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Investor Relations

Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com


		2/3

Sanofi forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025, or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties, and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group.


		3/3

EX-99.4 5 d137048dex994.htm EX-99.4 EX-99.4

Exhibit 99.4


Press Release

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

•

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study program

•

CSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolled

•

CSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of age

Paris and Tarrytown, NY, April 22, 2026. The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children aged two to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine (H1AH) treatment. This expands the previous approval for Dupixent in adults and adolescents aged 12 years and older with CSU.

“Children with uncontrolled chronic spontaneous urticaria continue to experience the unpredictable appearance of debilitating itch and hives,” said Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology Development at Sanofi. “Until now, these patients had to rely on limited treatment options that didn’t address potential critical mediators of chronic spontaneous urticaria. Dupixent is the first biologic approved for patients as young as two years of age, offering a targeted approach that inhibits IL4 and IL13 signaling, two key and central drivers of the type 2 inflammation that contributes to this disease. Today’s approval underscores our ongoing commitment to advancing therapies for young patients with significant unmet needs.”

The approval is based primarily on data from the LIBERTY-CUPID clinical study program. This includes extrapolation of efficacy and safety data from two phase 3 studies (Study A and Study C; clinical study identifier: NCT04180488) in certain adults and adolescents aged 12 years and older with CSU complemented with pharmacokinetics data from the single-arm, CUPIDKids (clinical study identifier: NCT05526521) phase 3 study in children aged 2 to 11 years with CSU. In Study A and Study C, Dupixent significantly reduced itch severity and urticaria activity (a composite of itch and hives) compared to placebo at Week 24. In adults and adolescents, Dupixent also increased the likelihood of well-controlled disease or complete response compared to placebo at Week 24. Study B (clinical study identifier: NCT04180488) provided additional safety data and evaluated Dupixent in patients aged 12 years and older who were inadequate responders or intolerant to anti-IgE therapy and symptomatic despite antihistamine use. Safety in children aged 2 to 11 years with CSU was supported by data from pediatric patients in other indications.

The safety results from all four CSU studies were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. In Study A, Study B, and Study C, the most common adverse reaction (≥2%) in the US Prescribing Information more frequently observed in patients on Dupixent compared to placebo was injection site reactions. No new adverse reactions were identified in children aged 2 to 11 years with CSU treated with Dupixent.

“With this approval, Dupixent has become the first biologic medicine in the US for young children suffering from uncontrolled chronic spontaneous urticaria, an unpredictable skin disease that impacts quality of life during these children’s most formative years,” said George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer at Regeneron. “Dupixent is now approved for nine different allergy-related conditions, from asthma to atopic dermatitis, and this is the fifth of these indications now extended to young children. The FDA’s authorization reinforces our medicine’s well-established safety profile and potential to transform outcomes for chronic diseases driven in part by type 2 inflammation impacting some of the most vulnerable populations. As the most widely used innovative branded antibody medicine, Dupixent, has the potential to change yet another treatment paradigm.”

In addition to the US, Dupixent is approved for CSU in certain children aged two to 11 years in the EU and other countries around the world.

About CSU

CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1AH, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However, the disease remains uncontrolled despite H1AH treatment in more than 14,000 children in the US aged two to 11 years living with CSU, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their quality of life.

About the Dupixent CSU phase 3 study program

The LIBERTY-CUPID phase 3 program evaluating Dupixent for CSU in children aged two to 11 years consists of CUPIDKids, Study A, Study B and Study C. CUPIDKids was a single arm clinical study that assessed the safety, efficacy, and pharmacokinetics of Dupixent in children aged two to 11 years with CSU who remained symptomatic despite the use of antihistamines. During the 24-week treatment period, Dupixent was administered at 200 mg every two (Q2W) or four (Q4W) weeks or 300 mg Q4W, with or without an initial loading dose, based on age and weight. The primary endpoint measured the serum concentration of Dupixent over time, including C_trough (lowest concentration before the next dose) at Week 12 and Week 24.

Study A and Study C were replicate, double-blind, placebo-controlled clinical studies that assessed Dupixent as an add-on therapy to standard-of-care antihistamines compared to antihistamines alone in patients aged six years and older who remained symptomatic despite the use of antihistamines and were naïve to anti-Immunoglobulin E therapy. Study B was conducted in patients aged 12 years and older who were symptomatic despite use of antihistamines and were inadequate responders or intolerant to anti-IgE therapy. During the 24-week treatment period in all three studies, all patients received an initial loading dose followed by either 300 mg Dupixent Q2W or, for pediatric patients weighing 30 kg to <60 kg, 200 mg Q2W. In both studies, endpoints assessed at Week 24 included:

•

Change from baseline in itch (measured by the weekly itch severity score, 0-21 scale), the primary endpoint

•

Change from baseline in itch and hives (weekly urticaria activity score [UAS7], 0-42 scale), the key secondary endpoint

•

Proportion of patients achieving well-controlled disease status (UAS7 ≤6)

•

Proportion of patients with complete response (UAS7=0)

About Dupixent

Dupixent (dupilumab) is an injection administered under the skin (subcutaneous injection) at different injection sites. In children aged two to 11 years with CSU who remain symptomatic despite H1AH treatment, Dupixent is administered based on age and weight. In children aged two to five years, Dupixent is administered at 200 mg Q4W for patients weighing ≥5 kg to <15 kg and 300 mg Q4W for ≥15 kg to <30 kg, without an initial loading dose. In children aged six to 17 years, Dupixent is administered at 300 mg Q4W for ≥15 kg to <30 kg, 200 mg Q2W for ≥30 kg to <60 kg, and 300mg Q2W for ≥60 kg, after an initial loading dose. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. In children aged two to 11 years, Dupixent should be administered by a caregiver if given at home.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay^® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, CSU, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis in different age populations. More than 1.4 million patients are being treated with Dupixent globally.

Dupilumab development program

Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 12,000 patients with various chronic diseases driven in part by type 2 inflammation.

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 420 926 6780 | ekaterina.pesheva@sanofi.com

Sanofi Investor Relations

Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com

Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Regeneron Media Relations

Ilana Yellen| +1 914-330-9618 | ilana.yellen@regeneron.com

Regeneron Investor Relations

Mark Hudson | +1 914-847-3482 | mark.hudson@regeneron.com

Sanofi forward-looking statements

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Regeneron Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent^® (dupilumab) for the treatment of children aged 2 to 11 years with chronic spontaneous urticaria; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

EX-99.5 6 d137048dex995.htm EX-99.5 EX-99.5

Exhibit 99.5


Press Release

Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

•

Recommendation based on the HERCULES phase 3 study which demonstrated that brain-penetrant Cenrifki (tolebrutinib) significantly delayed the onset of disability progression in non-relapsing SPMS

Paris, April 24, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Cenrifki (tolebrutinib) in the EU for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. A final decision is expected in the coming months.

SPMS is a debilitating stage of multiple sclerosis where patients experience continuous accumulation of disability, including fatigue, cognitive impairment, mobility difficulties, and loss of independence – often without available treatment options. Addressing disability progression remains one of the most significant unmet needs in MS care.

The positive CHMP opinion is based on data from the HERCULES phase 3 study (clinical study identifier: NCT04411641) in non-relapsing SPMS, with supporting data from the GEMINI 1 (clinical study identifier: NCT04410978) and GEMINI 2 (clinical study identifier: NCT04410991) phase 3 studies in relapsing multiple sclerosis (RMS), which were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Conference 2024, the American Academy of Neurology (AAN) 2025 Annual Meeting, and published in The New England Journal of Medicine. The safety profile of Cenrifki has been consistent across the clinical program. Most common adverse events were COVID-19 and upper respiratory tract infections. Significant liver enzyme elevations were also observed. Drug-induced liver injury (DILI) is an identified safety risk of tolebrutinib. Strict adherence to liver monitoring requirements, and prompt management of liver enzyme elevations, are important to mitigate DILI risk.

Additional submissions for Cenrifki are currently under review with regulatory authorities worldwide.

About Cenrifki

Cenrifki (tolebrutinib) is an oral, brain-penetrant Bruton’s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS. This mechanism addresses the underlying pathology of secondary progressive MS by targeting the inflammatory processes that contribute to disability accumulation.

Cenrifki represents Sanofi’s commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape. Standing at the intersection of neurology and immunoscience, Sanofi is focused on improving the lives of those living with serious neuroinflammatory and neurodegenerative conditions including MS, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease, Parkinson’s disease, age-related macular degeneration, and other neurological diseases. The neurology pipeline currently has several projects in phase 3 studies across various diseases.


		1/2

About Sanofi

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com

Investor Relations

Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group.


		2/2

GRAPHIC 7 g137048g0205182740684.jpg GRAPHIC begin 644 g137048g0205182740684.jpg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end GRAPHIC 8 g137048g0206020218700.jpg GRAPHIC begin 644 g137048g0206020218700.jpg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g137048g0425064515920.jpg GRAPHIC begin 644 g137048g0425064515920.jpg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end GRAPHIC 10 g137048g0425065152033.jpg GRAPHIC begin 644 g137048g0425065152033.jpg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end